SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin gets US FDA nod for Epileptic drug

20 Oct 2011 Evaluate

Lupin Pharmaceuticals has received final approval from the US Food and Drug Administration (USFDA) to market the generic version of the anti-epileptic drug Keppra. The total sales of this drug in the US market is estimated to be $13 billion. Keppra was the patented drug of European drug maker UCB pharma. It lost the patent for this drug in 2008. The drug has been growing at 23% every year with a total sales of $1.74 billion

Lupin Share Price

2271.60 -106.30 (-4.47%)
11-May-2026 13:46 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1874.00
Dr. Reddys Lab 1295.00
Cipla 1321.95
Zydus Lifesciences 946.80
Lupin 2271.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×